Valiant Laboratories released its FY 2025-26 annual report showing a return to standalone profitability and a debt-free balance sheet following an Rs. 81.47 crore rights issue. While standalone revenue grew by 62.75%, consolidated losses widened due to startup costs at its new subsidiary, VASPL. The company is now focusing on scaling production in Gujarat and resolving pending tax adjudication matters.
Valiant Laboratories Reports Operational Turnaround in FY26
Revenue grew 78% YoY to Rs. 237.47 crore, while the company achieved a debt-free status.
Reader Takeaway: Improved standalone profitability and vertical integration provide growth potential, but elevated receivables and tax disputes remain significant headwinds.
What just happened
Valiant Laboratories released its Annual Report for FY 2025-26, highlighting a shift toward debt-free operations and increased operational capacity. On a standalone basis, the company reported a Profit After Tax (PAT) of Rs. 5.55 crore, a sharp turnaround from a loss of Rs. 2.15 crore in the previous year. Revenue from operations on a standalone basis surged 62.75% to Rs. 217.04 crore.
Why this matters
The company successfully utilized an Rs. 81.47 crore rights issue completed in August 2025 to eliminate term borrowings. This deleveraging is expected to reduce future interest expenses. Additionally, the commencement of commercial production at the Valiant Advanced Sciences (VASPL) facility in Saykha, Gujarat, provides backward integration for its core Paracetamol API business, potentially stabilizing margins against import volatility.
Risks to watch
Despite the standalone turnaround, consolidated net losses widened to Rs. 3.27 crore, attributed to high depreciation and finance costs associated with the new facility. Furthermore, management is currently contesting multiple tax-related adjudication orders, including a Rs. 57.25 lakh ITC dispute and a Rs. 36 lakh GST demand. Investors should also monitor high trade receivable days, which stood at approximately 127 days.
What to track next
Key milestones for the coming year include the throughput ramp-up of the VASPL facility and the achievement of WHO-GMP compliance. The resolution of ongoing tax litigation and the ability of management to reduce the high working capital cycle will be critical for sustaining the recent operational improvement.